It’s been a troublesome week for the psychedelics pioneer Rick Doblin.
First, the Meals and Drug Management declined to approve the MDMA-assisted treatment for post-traumatic tension dysfunction advanced by means of Lykos Therapeutics, an organization that he based. Tomorrow, the magazine Psychopharmacology retracted 3 research at the remedy, by which many authors have been related to Lykos or the nonprofit Doblin based, the Multidisciplinary Affiliation for Psychedelic Research (MAPS).
On Thursday, Lykos introduced it might reduce 75% of its team of workers — and Doblin left the corporate’s board. Now, MAPS is slicing 33% of its personal 42-person team of workers, it mentioned, so that you could preserve assets because it hones its focal point to drug decriminalization and globalizing get right of entry to to MDMA.
STAT+ Unique Tale
Have already got an account? Log in
This newsletter is unique to STAT+ subscribers
Release this newsletter — plus in-depth research, newsletters, top class occasions, and networking platform get right of entry to.
Have already got an account? Log in
Have already got an account? Log in
Person plans
Workforce plans
View All Plans
Get limitless get right of entry to to award-winning journalism and unique occasions.
Subscribe
